Overview

Ixazomib Rollover Study

Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide continued access to ixazomib and evaluation of the long-term safety profile of ixazomib.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Glycine
Ixazomib